Eventide Asset Management ROIV Position
Exited8-Fund ConvergenceEventide Asset Management exited their position in Roivant Sciences Ltd. (ROIV) in Q1 2024, after holding the stock for 5 quarters.
The position was first reported in Q1 2023 and has been tracked across 5 quarterly 13F filings.
ROIV is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Full company profile →Short Interest
4.3%
4.1 days to cover
Eventide Asset Management ROIV Position History
Frequently Asked Questions
Does Eventide Asset Management own ROIV?
No. Eventide Asset Management exited their position in Roivant Sciences Ltd. (ROIV) in Q1 2024. They previously held the stock for 5 quarters.
How many hedge funds own ROIV?
8 specialist biotech hedge funds currently hold ROIV, including Perceptive Advisors, Baker Bros. Advisors, Avoro Capital Advisors and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy ROIV?
Eventide Asset Management's position in ROIV was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's ROIV position increasing or decreasing?
Eventide Asset Management completely exited their ROIV position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ROIVCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →